AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010
09 Apr 2024
ImmunotherapyAACRVaccine
LYON, France--(BUSINESS WIRE)-- Brenus Pharma unveils groundbreaking results during the American Association Cancer Research (AACR) Annual meeting 2024 – San Diego (April 5-10).
“Efficacy of the STC-10101 a new allogeneic cancer vaccine in different colorectal cancer models” | Abstract 5003
This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.
Additionally, multi-omics analysis of STC-1010 batches confirmed consistent quality and batch-to-batch reproducibility, through standardized and scalable production.
STC-1010 was tested in several models extrapolating human conditions (ex-vivo; in-ovo,) using PBMCs from different donors. Results showed a significant immune response activation coupled with a massive and robust tumor killing that has been consistent with our 3 latest STC1010 batches manufactured. Metastasis reduction has also been shown with in-ovo model.
Results show the potential of STC-1010 in clinical settings to treat patients with colorectal cancer causing 9.7 million death per year.
George ALZEEB2, galzeeb@brenus-pharma.com, Innovation Manager Manager (Ph.D)
Céline GONGORA3, celine.gongora@inserm.fr, Research Director, Head of Team Inserm U1194 “Drug resistances and new cancer treatment” (Ph.D)
Corentin RICHARD4, CRichard@cgfl.fr, Postdoctoral Bioiformatician (Ph.D)
Romain BOIDOT3, rboidot@cgfl.fr, Molecular Biologist (Ph.D)
Tanguy FORTIN5, tanguy.fortin@anaquant.com, Chief Executive Officer (Ph.D)
Yan WANG6, yan.wang@inovotion.com, Scientist/R&D Project Manager (Ph.D)
Alban BESSEDE7, a.bessede@explicyte.com, Chief Executive Officer (Ph.D)
Benoit PINTEUR1, bpinteur@brenus-pharma.com, Chief Scientific Officer (Pharm D)
Lionel CHALUS1, lchalus@brenus-pharma.com, Head of Technical Operation
Corinne TORTORELLI1, ctortorelli@brenus-pharma.com, Senior Medical Lead (Pharm.D., Ph.D)
Paul BRAVETTI1, pbravetti@brenus-pharma.com, Chief Executive Officer (Pharm D, MSc)
François GHIRINGHELLI8, FGhiringhelli@cgfl.fr, Head of Team Inserm 1231 TIRECs «Therapies and Immune REsponse in CancerS », Director of early clinical unit CLIPP2, Professor of Oncology (M.D, PhD)
| Follow us on LinkedIn
1 STC-1010 is a next-generation cancer immunotherapy produced by Allogeneic STC's proprietary Brenus platform. It’s specifically designed to combat colorectal cancer including MSS and MSI-H populations in its first line of treatment for the first indication. STC Platform mimics relapse conditions and allows eduction of patient’s immune system against resistant tumor.
2 Brenus Pharma, Lyon, France,
3 INSERM U1194 IRCM, Montpellier, France,
4 CNRS 6302, Dijon, France,
5 Anaquant, Lyon, France
6 Inovotion, La Tronche, France,
7 Explicyte, Bordeaux, France
8 Inserm 1231 CGFL, Dijon, France
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.